Patient baseline characteristics
| All patients (n = 34) | |
| Gender | N (%) |
| Male | 19 (56) |
| Female | 15 (54) |
| Age, median (range) | 58 (32–79) |
| ECOG performance status | |
| 0 | 14 |
| 1 | 20 |
| Carcinomas (n = 23) | |
| Gender | N (%) |
| Male | 1 (4) |
| Female | 22 (96) |
| Age, median (range) | 52 (32–79) |
| Tumor type | N (%) |
| Colorectal | 11 (32) |
| Chordoma | 11 (32) |
| Breast | 5 (15) |
| Pancreatic | 3 (9) |
| Prostate | 2 (6) |
| Urothelial | 1 (3) |
| Lung | 1 (3) |
| Disease at study entry | N (%) |
| Stable disease | 1 (4) |
| Progressive disease | 22 (96) |
| Prior cytotoxic regimens | |
| 0 | 1 |
| 1 | 2 |
| 2 | 8 |
| ≥3 | 12 |
| Chordoma (n = 11) | |
| Gender | N (%) |
| Male | 10 (91) |
| Female | 1 (9) |
| Age, median (range) | 58.5 (32–66) |
| Tumor anatomical location | |
| Sacral | 6 (55) |
| Clival | 3 (27) |
| Spinal | 2 (18) |
| Disease at study entry | N (%) |
| Stable disease | 2 (18) |
| Progressive disease | 9 (82) |
| Prior therapy | N (%) |
| Surgery | 11 (100) |
| Radiotherapy | 11 (100) |
| Systemic therapy | 5 (45) |
| All patients (n = 34) | |
| Gender | N (%) |
| Male | 19 (56) |
| Female | 15 (54) |
| Age, median (range) | 58 (32–79) |
| ECOG performance status | |
| 0 | 14 |
| 1 | 20 |
| Carcinomas (n = 23) | |
| Gender | N (%) |
| Male | 1 (4) |
| Female | 22 (96) |
| Age, median (range) | 52 (32–79) |
| Tumor type | N (%) |
| Colorectal | 11 (32) |
| Chordoma | 11 (32) |
| Breast | 5 (15) |
| Pancreatic | 3 (9) |
| Prostate | 2 (6) |
| Urothelial | 1 (3) |
| Lung | 1 (3) |
| Disease at study entry | N (%) |
| Stable disease | 1 (4) |
| Progressive disease | 22 (96) |
| Prior cytotoxic regimens | |
| 0 | 1 |
| 1 | 2 |
| 2 | 8 |
| ≥3 | 12 |
| Chordoma (n = 11) | |
| Gender | N (%) |
| Male | 10 (91) |
| Female | 1 (9) |
| Age, median (range) | 58.5 (32–66) |
| Tumor anatomical location | |
| Sacral | 6 (55) |
| Clival | 3 (27) |
| Spinal | 2 (18) |
| Disease at study entry | N (%) |
| Stable disease | 2 (18) |
| Progressive disease | 9 (82) |
| Prior therapy | N (%) |
| Surgery | 11 (100) |
| Radiotherapy | 11 (100) |
| Systemic therapy | 5 (45) |